By a News Reporter-Staff News Editor at Biotech Week — From Alexandria, Virginia, NewsRx journalists report that a patent by the inventors Ghidini, Eleonora (Parma, IT); Capelli, Anna Maria (Parma, IT), filed on July 30, 2012, was published online on April 29, 2014 (see also Chiesi Farmaceutici S.p.A.).
The patent’s assignee for patent number 8710037 is Chiesi Farmaceutici S.p.A. (Parma, IT).
News editors obtained the following quote from the background information supplied by the inventors: “The present invention relates to novel anti-inflammatory and anti-allergic compounds of the glucocorticosteroid series, methods of preparing such a compound, and pharmaceutical compositions which contain such a compound. The present invention also relates to combinations of such a compound and another active agent and to therapeutic uses of such a compound. More particularly, the present invention relates to glucocorticosteroids that are derivatives of pyrrolidine.
“Corticosteroids are potent anti-inflammatory agents, able to decrease the number, activity, and movement of inflammatory cells. Corticosteroids are commonly used to treat a wide range of chronic and acute inflammatory conditions including asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, rheumatoid arthritis, inflammatory bowel disease and autoimmune diseases.
“Corticosteroids mediate their effects through the glucocorticoid receptor (GR). The binding of corticosteroids to GR induces its nuclear translocation which, in turn, affects a number of downstream pathways via DNA-binding-dependent (e.g. transactivation) and DNA-binding-independent (e.g. transrepression) mechanisms.
“Corticosteroids for treating chronic inflammatory conditions in the lung such as asthma and COPD are currently administered through inhalation. One of the advantages of employing inhaled corticosteroids (ICS) is the possibility of delivering the drug directly at the site of action, limiting systemic side-effects, thus resulting in a more rapid clinical response and a higher therapeutic ratio.
“Although ICS treatment can yield important benefits, especially in asthma, it is important to minimize ICS systemic exposure which leads to the occurrence and severity of unwanted side effects that may be associated with chronic administration. Moreover, the limited duration of action of ICS currently available in the clinical practice contributes to suboptimal management of the disease. While the inhaler technology is the key point to target the lung, the modulation of the substituents on the corticosteroids molecular scaffold is important for the optimization of pharmacokinetic and pharmacodynamic properties in order to decrease oral bioavailability, confine pharmacological activity only in the lung (prodrugs and soft drugs) and increase systemic clearance. Moreover, long lasting ICS activity in the lung is highly desirable as once daily administration of ICS would allow the reduction of the frequency of administration and, thus, substantially improve patient compliance and, as a result, disease management and control. In sum, there is a pressing medical need for developing ICS with improved pharmacokinetic and pharmacodynamic characteristics.
“Fluticasone furoate is an example of an enhanced affinity glucocorticoid that has been developed as topical therapy for allergic rhinitis with a unique combination of pharmacodynamic and physicochemical properties which render this compound long acting in the lung and rapidly inactivated by hepatic metabolism to reduce systemic side effects (Salter M, Biggadike K, Clackers M, et al. Fluticasone furoate (FF): enhanced cellular and tissue protection with a new selective glucocorticoid agonist [abstract no P212] Ann Allergy Asthma Immunol. 2007; 98:A89, which is incorporated herein by reference in its entirety).
“Glucocorticoid pyrrolidine derivatives have not been described, except for the co-pending patent application PCT/EP2011/051537, which is incorporated herein by reference in its entirety, in which some pyrrolidine derivatives were described.
“Thus, there remains a need for glucocorticoids with improved properties.”
As a supplement to the background information on this patent, NewsRx correspondents also obtained the inventors’ summary information for this patent: “Accordingly, it is one object of the present invention to provide novel glucocorticoids.
“It is another object of the present invention to provide novel methods of preparing such a glucocorticoid.
“It is another object of the present invention to provide novel pharmaceutical compositions which contain such a glucocorticoid.
“It is another object of the present invention to provide novel combinations which contain such a glucocorticoid and at least one other active agent.
“It is another object of the present invention to provide novel methods of treating and/or preventing certain diseases and/or conditions by administering such a glucocorticoid.
“These and other objects, which will become apparent during the following detailed description, have been achieved by the inventors’ discovery that compounds of general formula (I), and the corresponding compounds of general formula (I’) wherein, the configuration of some stereogenic centers is fixed are effective as glucocorticoids.
“##STR00001##
“The present invention also provides pharmaceutically acceptable acid addition salts of compounds of formula (I) and (I’), methods of preparing such a compound, combinations of such a compound with one or more active ingredients selected from the classes of .beta.2-agonist, antimuscarinic agents, PDE4 inhibitors, P38 MAP kinase inhibitors and IKK2 inhibitors, pharmaceutical compositions containing such a compound, and therapeutic uses of such a compound or pharmaceutically acceptable salt.
“Surprisingly, it has been found that the compounds of the invention show a particular good potency.”
For additional information on this patent, see: Ghidini, Eleonora; Capelli, Anna Maria. Pyrrolidine Derivatives, Pharmaceutical Compositions Containing the Same, and Methods of Using the Same. U.S. Patent Number 8710037, filed July 30, 2012, and published online on April 29, 2014. Patent URL: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=84&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=4179&f=G&l=50&co1=AND&d=PTXT&s1=20140429.PD.&OS=ISD/20140429&RS=ISD/20140429
Keywords for this news article include: Drugs, Asthma, Therapy, Fluticasone, Nasal Steroids, Topical Agents, Glucocorticoids, Topical Steroids, Bronchial Diseases, Respiratory Agents, Dermatological Agents, Immune System Diseases, Adrenal Cortex Hormones, Inhaled Corticosteroids, Obstructive Lung Diseases, Chiesi Farmaceutici S.p.A., Respiratory Tract Diseases.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC